CN1868460A - 注射用盐酸多西环素冻干制剂及其制备工艺 - Google Patents
注射用盐酸多西环素冻干制剂及其制备工艺 Download PDFInfo
- Publication number
- CN1868460A CN1868460A CN 200610035153 CN200610035153A CN1868460A CN 1868460 A CN1868460 A CN 1868460A CN 200610035153 CN200610035153 CN 200610035153 CN 200610035153 A CN200610035153 A CN 200610035153A CN 1868460 A CN1868460 A CN 1868460A
- Authority
- CN
- China
- Prior art keywords
- doxycycline hydrochloride
- injection
- doxycycline
- glycine
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960004082 doxycycline hydrochloride Drugs 0.000 title claims abstract description 66
- 239000007924 injection Substances 0.000 title claims abstract description 49
- 238000002347 injection Methods 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- 238000004108 freeze drying Methods 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 239000008215 water for injection Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 229960003722 doxycycline Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003610 charcoal Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 229940105082 medicinal charcoal Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 38
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 206010018910 Haemolysis Diseases 0.000 description 11
- 230000008588 hemolysis Effects 0.000 description 11
- 238000005352 clarification Methods 0.000 description 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000008354 sodium chloride injection Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003616 anti-epidemic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010028282 Murine typhus Diseases 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- -1 carboxamide hydrochloride Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000005901 endemic typhus Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940081561 rocephin Drugs 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- KTAVBOYXMBQFGR-MAODNAKNSA-J tetrasodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C KTAVBOYXMBQFGR-MAODNAKNSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
分值 | 体征 |
012 | 无明显反应轻微抓鼻、颤抖或竖毛出现咳嗽,多次抓鼻、颤抖或竖毛 |
34 | 多次或连续咳嗽,伴有呼吸困难或痉挛、抽搐痉挛、抽搐、大小便失禁、休克死亡 |
组别 | 动物数(只) | 评分 | 平均值(SD) | ||
1# | 2# | 3# | |||
第14天攻击:0.9%氯化钠注射液阴性组5%卵白蛋白阳性组注射用盐酸多西环素组第21天攻击:0.9%氯化钠注射液阴性组5%卵白蛋白阳性组注射用盐酸多西环素组 | 333333 | 040040 | 040040 | 040040 | 04.0 0±0.00004.00±0.000 |
管号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
2%红细胞悬液(ml)受试品(ml)生理盐水(ml)蒸馏水(ml) | 2.50.12.4- | 2.50.22.3- | 2.50.32.2- | 2.50.42.1- | 2.50.52.0- | 2.5-2.5- | 2.5--2.5 |
全溶血 | 溶液澄明红色,管底无细胞残留; |
部分溶血无溶血凝集 | 溶液澄明红色或棕色,管底有少量红细胞残留;红细胞全部下沉,上层液体无色澄明;红细胞聚集成块,振摇后不能分散; |
批号 | 时间(月) | 性状 | 酸度(pH值) | 溶液的澄清度 | 澄明度 | 干燥失重(%) | 土霉素(%) | 美他环素(%) | β-多西环素 | 含量(%) |
1 | 01824 | 淡黄色疏松块状物淡黄色疏松块状物淡黄色疏松块状物 | 2.32.22.3 | 澄清澄清澄清 | 符合规定符合规定符合规定 | 2.3/2.5 | 0.10.40.6 | 1.21.41.5 | 1.11.81.8 | 100.5100.2100.5 |
2 | 01824 | 淡黄色疏松块状物淡黄色疏松块状物淡黄色疏松块状物 | 2.22.22.3 | 澄清澄清澄清 | 符合规定符合规定符合规定 | 2.0/2.1 | 0.20.50.5 | 1.11.31.7 | 1.21.81.8 | 101.4100.9101.1 |
3 | 01824 | 淡黄色疏松块状物淡黄色疏松块状物淡黄色疏松块状物 | 2.32.32.3 | 澄清澄清澄清 | 符合规定符合规定符合规定 | 2.2/2.2 | 0.20.40.5 | 1.01.41.5 | 1.21.81.9 | 102.2101.8101.7 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100351535A CN100370992C (zh) | 2006-04-19 | 2006-04-19 | 注射用盐酸多西环素冻干制剂及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100351535A CN100370992C (zh) | 2006-04-19 | 2006-04-19 | 注射用盐酸多西环素冻干制剂及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1868460A true CN1868460A (zh) | 2006-11-29 |
CN100370992C CN100370992C (zh) | 2008-02-27 |
Family
ID=37442327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100351535A Expired - Fee Related CN100370992C (zh) | 2006-04-19 | 2006-04-19 | 注射用盐酸多西环素冻干制剂及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100370992C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618025B (zh) * | 2009-08-06 | 2011-08-31 | 齐鲁动物保健品有限公司 | 一种兽用盐酸多西环素冻干制剂及其制备方法 |
CN104739782A (zh) * | 2015-04-03 | 2015-07-01 | 海南通用康力制药有限公司 | 一种盐酸多西环素冻干粉针注射剂及其制备方法 |
CN105078905A (zh) * | 2015-08-13 | 2015-11-25 | 海南通用康力制药有限公司 | 一种注射用盐酸多西环素冻干粉针剂的制备方法 |
CN108815124A (zh) * | 2018-09-12 | 2018-11-16 | 海南通用康力制药有限公司 | 一种注射用盐酸多西环素冻干粉针剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568996A (zh) * | 2004-05-10 | 2005-01-26 | 郭东宇 | 一种盐酸环丙沙星冻干制剂及制备方法 |
-
2006
- 2006-04-19 CN CNB2006100351535A patent/CN100370992C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618025B (zh) * | 2009-08-06 | 2011-08-31 | 齐鲁动物保健品有限公司 | 一种兽用盐酸多西环素冻干制剂及其制备方法 |
CN104739782A (zh) * | 2015-04-03 | 2015-07-01 | 海南通用康力制药有限公司 | 一种盐酸多西环素冻干粉针注射剂及其制备方法 |
CN105078905A (zh) * | 2015-08-13 | 2015-11-25 | 海南通用康力制药有限公司 | 一种注射用盐酸多西环素冻干粉针剂的制备方法 |
CN105078905B (zh) * | 2015-08-13 | 2017-10-20 | 海南通用康力制药有限公司 | 一种注射用盐酸多西环素冻干粉针剂的制备方法 |
CN108815124A (zh) * | 2018-09-12 | 2018-11-16 | 海南通用康力制药有限公司 | 一种注射用盐酸多西环素冻干粉针剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100370992C (zh) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104922158B (zh) | 粪菌胶囊及其制备与应用 | |
US8092793B2 (en) | Treating inflammatory bowel disease with live bacteria | |
CN1883275A (zh) | 一种植物抗生素及其应用 | |
CN1868460A (zh) | 注射用盐酸多西环素冻干制剂及其制备工艺 | |
EP1954800A2 (en) | Composition and use of phyto-percolate for treatment of disease | |
WO2016053142A1 (ru) | Композиция для детоксикации организма | |
CN112852670B (zh) | 一种婴儿双歧杆菌dh231及其发酵产物、应用和微生态制剂 | |
CN109628311A (zh) | 用于保护肠道菌的冻干保护剂、冻干粉、胶囊及其制备方法 | |
Sorbello et al. | Infective endocarditis due to Pasteurella dagmatis: case report and review | |
WO2024051180A1 (zh) | 苯基乳酸在抑制幽门螺杆菌感染中的应用 | |
Boranbayeva et al. | Comparative Pharmacotherapeutic effectiveness of Therapeutic Ointments in infectious Keratoconjunctivitis in cattle | |
CN114699424B (zh) | 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用 | |
EP0363491A1 (fr) | Preparation bacterienne pour prophylaxie et traitement de processus inflammatoires et d'affections allergiques | |
CN116392511A (zh) | 鼠李糖乳杆菌外膜囊泡的制法和应用及外膜囊泡制品 | |
CN108670951A (zh) | 一种兽用硫酸庆大霉素-盐酸林可霉素复方缓释注射液及其制备方法 | |
RU2526571C1 (ru) | Инъекционный препарат для повышения спермопродукции человека и способ его применения | |
CN107158067B (zh) | 一种用于防治猪附红细胞体病的中药组合物及其制备方法和应用 | |
CN1299684C (zh) | 水产动物抗菌药及其制备方法 | |
Kamnerddee et al. | Dietary supplementation with Zooshikella marina improves growth performance, haemato-immunological parameters and disease resistance against Streptococcus agalactiae in Nile Tilapia (Oreochromis niloticus). | |
CN114933993B (zh) | 一种解木聚糖拟杆菌及其复合制剂在缓解溃疡性结肠炎中的应用 | |
CN108904482B (zh) | 苯丙酮酸在制备免疫增强剂中的应用 | |
Ali et al. | HISTOLOGICAL CHANGES AND IMMUNOSUPPRESSION INDUCE BY LEAD IN FEMALE RATS | |
CN1488349A (zh) | 门冬氨酸洛美沙星粉剂及其制备方法 | |
CN1726913A (zh) | 盐酸莫西沙星粉针剂及制备方法 | |
RU2246957C2 (ru) | Способ лечения хронического h.pylori-ассоциированного гастрита препаратом ламинолакт |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG WEILUN BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Assignor: Shantou Jianxin Pharmaceutical Co.,Ltd. Contract fulfillment period: 2009.10.1 to 2019.10.1 Contract record no.: 2010440000128 Denomination of invention: Doxycycline hydrochloride freeze-dried power prepn. for injection, and process for preparing same Granted publication date: 20080227 License type: Exclusive license Record date: 20100118 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.1 TO 2019.10.1; CHANGE OF CONTRACT Name of requester: GUANGDONG WELLEN BIOLOGICAL PHARMACEUTICAL CO., LT Effective date: 20100118 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: GUANGDONG WEILUN BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Assignor: Shantou Jianxin Pharmaceutical Co.,Ltd. Contract record no.: 2010440000128 Date of cancellation: 20140228 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG JIANXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANXIN MEDICAMENTS CO., LTD., SHANTOU CITY Effective date: 20140821 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 515041 SHANTOU, GUANGDONG PROVINCE TO: 515071 SHANTOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140821 Address after: 515071 Guangdong city of Shantou province Haojiang District Chu Pu Industrial District Fifth Building 6 floor Patentee after: GUANGDONG JIANXIN PHARMACEUTICAL Co.,Ltd. Address before: 515041 Guangdong Province, Shantou City Hanjiang Changping Road Building Room 1003 Patentee before: Shantou Jianxin Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 515071 Guangdong province Shantou City Sanlian Industrial Zone Haojiang District Chu Pu District letter Pharmaceutical Industrial Park Patentee after: GUANGDONG JIANXIN PHARMACEUTICAL Corp.,Ltd. Address before: 515071 Guangdong city of Shantou province Haojiang District Chu Pu Industrial District Fifth Building 6 floor Patentee before: GUANGDONG JIANXIN PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080227 |
|
CF01 | Termination of patent right due to non-payment of annual fee |